Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 28
GLP-1 drugs and skin: what JAAD flagged
A new JAAD editorial puts skin changes and medicolegal questions around semaglutide and tirzepatide on the dermatology agenda.
Oral semaglutide nanomicelles in mice
A mouse study tests dual-transporter-targeted semaglutide nanomicelles. The early result is about delivery science, not a new treatment.
Regenerative Peptides for Tissue Repair
A 2026 review finds limited human evidence for many regenerative peptides used for tissue repair and chronic pain claims.
Tirzepatide weight loss outcomes in PCOS
A UK real-world study found similar 10-month tirzepatide weight loss in women with self-reported PCOS and women without PCOS.
Retatrutide and Heart-Risk Biomarkers
A post hoc analysis of two retatrutide Phase 2 trials found large drops in atherogenic lipoproteins and CRP, not proof of fewer cardiovascular events.
BPC-157 and TB-500 for Endurance Running
A recurring r/peptides question asks if the wolverine stack helps runners. No human trial has tested it, and both peptides remain unapproved drugs.
GLP-1 Drugs and Kidney Fibrosis in Mice
A new mouse study compared semaglutide, tirzepatide and retatrutide on kidney fibrosis. Here is what the animal data does and does not show.
GLP-1 drugs: eye and mood safety signals
A new pharmacovigilance study flags eye and psychiatric signals with semaglutide. Here is what it found, and what regulators already concluded.
GLP-1 Drugs and Psoriasis: Real-World Data
A JEADV cohort letter finds GLP-1 and dual GLP-1/GIP agonists associated with changes in healthcare resource use among patients with established psoriasis.
GLP-1 drugs in IIH: what research shows
A 2026 Headache meta-analysis finds GLP-1 receptor agonists reduce intracranial pressure and headache days in IIH. What the data shows.
Selank and Semax: what the research shows
Selank and Semax are paired on forums for anxiety and focus. Here is what published research shows about each, and why the combination has no clinical data.
Semaglutide gut transit: a 13C breath test
A 13C-mannitol breath test now tracks semaglutide gut transit delay in mice, noninvasively. Here is what the method reveals about GLP-1 effects on motility.